Forte Biosciences (FBRX) EBT Margin (2017 - 2019)
Forte Biosciences (FBRX) posted quarterly EBT Margin of 117588.89% for Q4 2019, up 9812222.0% year-over-year from N/an in Q4 2018, and up 43.51% quarter-over-quarter from 208166.67% in Q3 2019.
Powered by 
Analysis
Forte Biosciences (FBRX) EBT Margin (2017 - 2019) Analysis & Trends
Forte Biosciences (FBRX) has reported EBT Margin for 3 consecutive years, with 117588.89% the latest figure, recorded in Q4 2019.
- In Q4 2019, EBT Margin rose 9812222.0% year-over-year to 117588.89%; the TTM figure through Dec 2019 stood at 131472.22% (down 13121021.0% YoY), while the FY2019 annual figure was 176430.56%, down 17616855.0% from the prior year.
- EBT Margin grew to 117588.89% in Q4 2019 per FBRX's latest filing, from 208166.67% in the prior quarter.
- Across five years, EBT Margin topped out at 6.25% in Q3 2018 and bottomed at 215711.11% in Q4 2018.
- Historically, EBT Margin has averaged 126955.59% across 3 years, with a median of 125140.0% in 2017.
- On a YoY basis, EBT Margin climbed as much as 16845556 bps in 2019 and fell as far as 20817292 bps in 2019.
- Forte Biosciences' EBT Margin stood at 108370.0% in 2017, then plunged by 99 bps to 215711.11% in 2018, then jumped by 45 bps to 117588.89% in 2019.
- Business Quant data shows FBRX's EBT Margin at 117588.89% in Q4 2019, 208166.67% in Q3 2019, and 10311.11% in Q2 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 12.09% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -2.67% |
| 10 | Forte Biosciences | 1.58 Bn | 1.23 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | -117,588.89% |
| Sep 30, 2019 | -208,166.67% |
| Jun 30, 2019 | -10,311.11% |
| Mar 31, 2019 | -189,822.22% |
| Dec 31, 2018 | -215,711.11% |
| Sep 30, 2018 | 6.25% |
| Jun 30, 2018 | -178,766.67% |
| Mar 31, 2018 | -143,111.11% |
| Dec 31, 2017 | -108,370.00% |
| Sep 30, 2017 | -99,530.00% |
| Jun 30, 2017 | -90,440.00% |